The newspaper El Economista publishes information that says that the health systems of the European Union dedicated close to 8.040 million euros to the acquisition of biosimilars in 2022, and that an increase in this expense is expected as more treatments enter the market due to loss of patents of the originals.
recently published
VI National Conference on Biosimilars
November 21 2024
Infographics published during Global Biosimilars Week 2024
November 15 2024
Biocon Biologics joins BioSim as a new member
October 30 2024
